Future studies should systematically evaluate whether there is therapeutic potential of augmented LFA-1/ICAM-1 interactions in enhancing CTT-mediated antitumor immune responses in murine tumor models, which could provide crucial mechanistic insights for optimizing CTT-based immunotherapy protocols and broadening their clinical applicability. The gene discussed is ICAM1; the disease is neoplasm.